Page last updated: 2024-12-11
neorustmicin a
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
neorustmicin A: active against wheat stem rust fungus; isolated from Micromonospora chalcea 1302-AV2; MF C21-H32-O5; structure given in first source; has also been isolated from Streptomyces galbus [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 6438862 |
CHEMBL ID | 284267 |
MeSH ID | M0137829 |
Synonyms (5)
Synonym |
---|
100157-26-4 |
neorustmicin a |
CHEMBL284267 |
(3r,5s,7e,9s,12e,14s)-14-ethyl-5-hydroxy-5-(hydroxymethyl)-3,7,9,13-tetramethyl-11-methylidene-1-oxacyclotetradeca-7,12-diene-2,4-dione |
erythronolide a, 6,7,10,11,12,20-hexadehydro-9-deoxo-3,5,6,11,12-pentadeoxy-4,17-dihydroxy-3-oxo- |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (5)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID39699 | In vitro antifungal activity against Aspergillus fumigatus TIMM1776; activity expressed as minimum inhibitory concentration | 2004 | Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1 | Novel galbonolide derivatives as IPC synthase inhibitors: design, synthesis and in vitro antifungal activities. |
AID45478 | In vitro antifungal activity against Candida albicans ATCC 90028; activity expressed as minimum inhibitory concentration | 2004 | Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1 | Novel galbonolide derivatives as IPC synthase inhibitors: design, synthesis and in vitro antifungal activities. |
AID202873 | In vitro antifungal activity against Saccharomyces cerevisiae Y9; activity expressed as minimum inhibitory concentration | 2004 | Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1 | Novel galbonolide derivatives as IPC synthase inhibitors: design, synthesis and in vitro antifungal activities. |
AID55035 | In vitro antifungal activity against Cryptococcus neoformans ATCC 9011; activity expressed as minimum inhibitory concentration | 2004 | Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1 | Novel galbonolide derivatives as IPC synthase inhibitors: design, synthesis and in vitro antifungal activities. |
AID54870 | In vitro antifungal activity against Cryptococcus neoformans ATCC 9011 | 2004 | Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1 | Novel galbonolide derivatives as IPC synthase inhibitors: design, synthesis and in vitro antifungal activities. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (8)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (37.50) | 18.7374 |
1990's | 1 (12.50) | 18.2507 |
2000's | 3 (37.50) | 29.6817 |
2010's | 1 (12.50) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.54
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.54) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |